FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:877-878 September 28, 1995 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Tsukuma, H. Related Article by Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire

To the Editor: In a group of patients with unresectable hepatocellular carcinoma but without severe liver disease, Trinchet et al. (May 11 issue)¹ found that chemoembolization with Lipiodol (iodized oil) reduced tumor growth, often caused acute liver failure, and did not significantly improve survival. Because of variations in protocols and in the levels of expertise with which chemoembolization is performed, the authors' conclusion that this therapy should not be recommended may not be applicable to many patients.

Regardless of the exact method used, there will be some degree of hepatic damage after embolization, and this accumulated injury following repeated chemoembolizations . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.